Analytical excellence supporting every stage of drug development. From discovery to commercialization, SGS delivers rigorous, phase‑appropriate analytical testing to ensure product quality, safety, and regulatory readiness.
SGS provides comprehensive analytical services that span the entire pharmaceutical development lifecycle—from early pre‑formulation through clinical release and commercial manufacturing. Our analytical scientists support small‑molecule and microbiome-based products with validated, phase‑appropriate methods that ensure robust decision‑making, regulatory compliance, and product quality.
Seamlessly integrated analytical workflows from discovery through commercialization ensure consistent data quality and reduced development risk.
Our experts build analytical methods that evolve with program needs—from early screening to full validation for clinical and regulatory submissions.
State‑of‑the‑art techniques for impurity profiling, stability‑indicating methods, nitrosamine testing, elemental analysis, and extractable/leachable studies.
Support for small molecules and microbiome APIs, including microbial purity, viability, and digital PCR analytics.
We provide critical support across all phases:
Discovery & Pre-clinical
Review / Approve & Commercial Manufacture
Clinical Development
Additionally, SGS offers specialized finished‑product analytics including stability‑indicating assays (HPLC/UPLC), dissolution and drug‑release profiling, impurity identification, chiral analysis, microbial purity, and dPCR for microbiome products.